WO2021238644A1 - 一种短肽型肠内营养制剂 - Google Patents
一种短肽型肠内营养制剂 Download PDFInfo
- Publication number
- WO2021238644A1 WO2021238644A1 PCT/CN2021/093128 CN2021093128W WO2021238644A1 WO 2021238644 A1 WO2021238644 A1 WO 2021238644A1 CN 2021093128 W CN2021093128 W CN 2021093128W WO 2021238644 A1 WO2021238644 A1 WO 2021238644A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- short peptide
- enteral nutrition
- nutrition preparation
- content
- per
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 20
- 239000004475 Arginine Substances 0.000 claims abstract description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 12
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 8
- 239000005862 Whey Substances 0.000 claims abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 6
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 6
- 230000035764 nutrition Effects 0.000 claims description 43
- 208000025721 COVID-19 Diseases 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 206010035737 Pneumonia viral Diseases 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 208000009421 viral pneumonia Diseases 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 229930091371 Fructose Natural products 0.000 abstract description 4
- 239000005715 Fructose Substances 0.000 abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 4
- 239000005913 Maltodextrin Substances 0.000 abstract description 4
- 229920002774 Maltodextrin Polymers 0.000 abstract description 4
- 229940035034 maltodextrin Drugs 0.000 abstract description 4
- 229930006000 Sucrose Natural products 0.000 abstract description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 235000010755 mineral Nutrition 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 239000005720 sucrose Substances 0.000 abstract description 3
- 239000011573 trace mineral Substances 0.000 abstract description 3
- 235000013619 trace mineral Nutrition 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 229960002737 fructose Drugs 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 230000036039 immunity Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021049 nutrient content Nutrition 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- -1 oligofructose Proteins 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the field of food and medicine, in particular to a short peptide enteral nutrition preparation.
- the application number is CN201410351455.8, a patent application for a short peptide immune-enhancing enteral nutrition emulsion and its preparation method. It discloses a patent application of high-quality protein peptides with high content and homologous medicinal and food ingredients.
- the combined action of the biologically active ingredients and synergistic effect can effectively improve the immune function of the body and provide nutritional support for cancer patients.
- Low immune function of COVID-19 (new coronary pneumonia) patients has become an important reason affecting the prognosis, including the "2020 ESPEN Expert Statement and Practice Guide: Nutrition Management of SARS-CoV-2 Infected Patients" issued by the European Society of Clinical Nutrition and Metabolism.
- COVID-19 patients with thick food to strengthen nutrition and improve the patient’s immunity.
- most patients with COVID-19 have gastrointestinal damage. Supplementing thick food is easy to bring to the digestive system of COVID-19 patients. An unbearable burden, some COVID-19 patients experienced dyspeptic diarrhea.
- the present invention aims to overcome the above-mentioned problems and provide a new pre-digested short peptide enteral nutrition preparation.
- a short peptide enteral nutrition preparation characterized in that the short peptide enteral nutrition preparation is a pre-digested nutritional supplement, and the short peptide nutrition is based on short peptides, medium chain fatty acids, branched chain amino acids or branched chain amino acids Dipeptide, arginine or arginine dipeptide, sucrose, fructose, glucose, maltodextrin, oligofructose, carnosine, glutamate dipeptide, vitamins, minerals and trace elements are pre-digested nutrition
- short peptides are preferably whey short peptides, or short peptides are preferably dipeptides and tripeptides. This product can be made into emulsion or powder.
- the nutrient content per 100mL is: short peptide (or whey short peptide, or dipeptide and tripeptide) 2.0g-10.0g, preferably 5.0g-8.0g, medium-chain fatty acid 2.0g-10.0g , Preferably 2.0g-8.0g, carbohydrate 2.0g-20.0g, preferably 5.0g-15.0g, arginine or arginine dipeptide 0.1g-3.0g, branched chain amino acid or branched chain amino acid dipeptide 0.2g- 3.0g.
- the nutrient content of each 100g of this short peptide nutrition is: short peptide (or whey short peptide, or dipeptide and tripeptide) 10.0g-50.0g, medium chain fatty acid 10.0g-40.0g, Carbohydrates 10.0g-65.0g, preferably 20.0g-50.0g, arginine or arginine dipeptide 0.5g-10.0g, branched chain amino acid or branched chain amino acid dipeptide 2.0g-20.0g.
- SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptor and furin (TMPRSS2) to enter the intestinal absorption cells and submucosal microvascular endothelial cells, causing diffuse inflammatory damage to the gastrointestinal tract in patients with COVID-19.
- ACE2 angiotensin-converting enzyme 2
- TMPRSS2 furin
- the nano short peptide group can significantly improve the prealbumin level of COVID-19 patients, and the average time for nucleic acid to become negative is shortened 38.78%, indicating that short nanopeptides can significantly increase the recovery speed of COVID-19 patients and improve the prognosis.
- Modern medicine has proven that the human intestine has amino acid channels and short peptide channels for protein absorption. Short peptides do not need to rely on the digestive function of the human body and can be directly absorbed by the gastrointestinal tract. 60%-80% of the human body’s immune cells are in the intestine.
- Short peptides can directly provide nutrition for the differentiation of intestinal immune cells and the synthesis of immunoglobulins, which has an unexpected effect.
- Arginine can significantly increase the weight of the thymus and strengthen T cells. Function, so as to achieve the purpose of improving immunity and speeding up the recovery of patients.
- the current viral infectious diseases known COVID-19, viral pneumonia, influenza, hepatitis B, viral myocarditis, hand-foot-mouth disease, chickenpox, measles, herpes, infantile acute eruption, mumps, all have no special effects
- Antiviral drugs mainly rely on human immunity to kill viruses. Most patients with viral infections have a certain degree of impaired digestive function, and the digestive and absorption function cannot meet the nutritional needs of patients with high metabolism caused by inflammation.
- the short peptide enteral nutrition preparation can be prepared in any ratio within the above range, and prepared into different formulas
- a series of medicines or foods are used to prevent and treat viral diseases, especially to prevent and treat COVID-19, viral pneumonia, influenza, and herpes, which can unexpectedly improve nutritional status and improve human immunity It can effectively kill the virus and achieve the purpose of preventing and curing such viral diseases.
- the advantages and effects of the present invention are that it replaces whole protein as a way of nutritional treatment for patients with viral infections.
- the short peptide nutrition directly provides nutrition for intestinal immune cell differentiation and synthesis of immunoglobulins, thereby improving immunity ,
- the invention has simple operation and low cost.
- This short peptide enteral nutrition preparation contains per 100mL: short peptide 3.5g, branched chain amino acid 0.5g, arginine dipeptide 0.5g, medium chain fatty acid 5.0g, maltodextrin 3.0g, fructose 9.0g ratio
- Ingredients dissolve the auxiliary materials such as pectin and other stabilizers with hot water, then add the auxiliary materials such as drinking water, salt, lactic acid, sweeteners, and then add the nutrient materials, stir evenly, set the volume and the acid, use a high-pressure homogenizer to average and fill Pack, sterilize, inspect, and package to make short peptide nutritional products.
- the short peptide nutritional product is used in the nutritional support treatment of COVID-19 patients to improve the patient's immunity. Usage: 200-300ml/time orally, 3-4 times a day.
- This short peptide enteral nutrition preparation per 100 grams of this short peptide nutrition, the nutrient content is: short peptide 20.0g, medium chain fatty acid 20.0g, arginine dipeptide 5.0g, branched chain amino acid dipeptide 10.0g , Sucrose 3.0g, fructose 10.0g, maltodextrin 30.0g, and added vitamins, minerals and trace elements. Then, it is mixed, sterilized, inspected, and packaged to make short peptide nutritional powder.
- the short peptide nutritional product is used for the nutritional support treatment of patients with influenza and viral pneumonia to improve the patient's immunity. Usage: 50-100 g/time, orally after dissolving in hot water, 3-4 times a day.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种短肽型肠内营养制剂，以短肽、乳清短肽、中链脂肪酸、支链氨基酸、精氨酸或精氨酸二肽、蔗糖、果糖、葡萄糖、麦芽糊精、维生素、矿物质和微量元素为原料制备而成。
Description
本发明涉及食品与医药领域，特别涉及一种短肽型肠内营养制剂。
在现有技术中，申请号为CN201410351455.8一种短肽免疫增强型肠内营养乳剂及其制备方法的专利申请，公开了一种通过高含量的优质蛋白肽以及药食同源各食材中的生物活性成分的共同作用，协同增效，能有效提高机体的免疫功能，为肿瘤患者提供营养支持。COVID-19（新冠肺炎）患者免疫功能低下成为了影响预后的重要原因，包括欧洲临床营养和代谢学会发布的《2020 ESPEN专家声明和实践指南：SARS-CoV-2感染患者的营养管理》等都在提倡给COVID-19患者提供浓稠食品来加强营养，提高患者免疫力，但COVID-19患者绝大部分都存在胃肠功能损伤，补充浓稠食品容易给COVID-19患者的消化***带来难以承受的负担，部分COVID-19患者出现了消化不良性腹泻。
本发明就是要克服上述问题，提供一种新的预消化的短肽型肠内营养制剂。
一种短肽型肠内营养制剂，其特征在于本短肽型肠内营养制剂为预消化型营养补充剂，本短肽型营养是以短肽、中链脂肪酸、支链氨基酸或支链氨基酸二肽、精氨酸或精氨酸二肽、蔗糖、果糖、葡萄糖、麦芽糊精、低聚果糖、肌肽、谷氨酸二肽、维生素、矿物质和微量元素为营养成分的预消化型营养补充剂，短肽优选乳清短肽，或者短肽优选二肽和三肽。本产品可制成乳剂或粉剂。制成乳剂时，每100mL的营养成分含量为：短肽（或者乳清短肽，或者二肽和三肽）2.0g-10.0g，优选5.0g-8.0g，中链脂肪酸2.0g-10.0g，优选2.0g-8.0g，碳水化合物2.0g-20.0g，优选5.0g-15.0g，精氨酸或精氨酸二肽0.1g-3.0g，支链氨基酸或支链氨基酸二肽0.2g-3.0g。制成粉剂时，每100克本短肽型营养的营养成分含量为：短肽（或者乳清短肽，或者二肽和三肽）10.0g-50.0g，中链脂肪酸10.0g-40.0g，碳水化合物10.0g-65.0g，优选20.0g-50.0g，精氨酸或精氨酸二肽0.5g-10.0g，支链氨基酸或支链氨基酸二肽2.0g-20.0g。SARS-CoV-2利用血管紧张素转换酶2(ACE2)受体和弗林蛋白酶（TMPRSS2）进入肠道吸收细胞和粘膜下微血管内皮细胞，引起COVID-19患者的胃肠道弥漫性炎症损害，这些炎症主要表现在小肠粘膜下的微血管病变和肠粘膜吸收性肠上皮细胞病变，使COVID-19患者的消化吸收功能受损严重，受损的消化吸收功能不能满足COVID-19患者炎症引起的高代谢的营养需求，导致99%的COVID-19患者出现了前白蛋白降低和免疫功能低下。通过比较短肽干预的治疗组（n=15）和整蛋白干预的对照组（n=51），纳米短肽组能显著改善COVID-19患者的前白蛋白水平，核酸转阴的平均时间缩短38.78%，说明纳米短肽能够显著提高COVID-19患者的康复速度，改善预后。现代医学已经证明，人体肠道对蛋白质的吸收具有氨基酸通道和短肽通道。短肽不需要依赖人体的消化功能，可以主动被胃肠道直接吸收。人体60%-80%的免疫细胞在肠道，短肽可以直接为肠道免疫细胞分化和合成免疫球蛋白提供营养，起到意想不到的效果，精氨酸可以显著增加胸腺重量，增强T细胞功能，从而达到提高免疫力，加快患者康复的目的。目前的病毒感染性疾病，已知的COVID-19、病毒性肺炎、流感、乙型肝炎、病毒性心肌炎、手足口病、水痘、麻疹、疱疹、幼儿急疹、流行性腮腺炎，都没有特效抗病毒药，主要靠人体免疫力杀死病毒。病毒感染的患者大部分都存在一定程度的消化功能受损，消化吸收功能不能满足患者炎症引起的高代谢的营养需求。营养不良可引起全身免疫功能降低，加强营养可以提高病人的免疫力，根据病人基础疾病和身体状况的要求，在上述范围内按任一比例制作本短肽型肠内营养制剂，制备成不同配方系列的药品或食品（包括医用食品），用于预防和治疗病毒性疾病，特别是预防和治疗COVID-19、病毒性肺炎、流感、疱疹，能起到意想不到的改善营养状况和提高人体免疫力来杀死病毒的效果，达到预防和治疗这类病毒性疾病的目的。
本发明的优点和效果在于代替了整蛋白作为病毒感染患者营养治疗的方式，本短肽型营养通过营养支持治疗，直接为肠道免疫细胞分化和合成免疫球蛋白提供营养，达到了提高免疫力，预防和治疗疾病，使患者快速康复的目的。本发明操作简单，成本较低。
本短肽型肠内营养制剂，按每100mL含有：短肽3.5g、支链氨基酸0.5g、精氨酸二肽0.5g、中链脂肪酸5.0g，麦芽糊精3.0g、果糖9.0g的比例配料，将辅料果胶等稳定剂用热水溶解，再加入饮用水、食盐、乳酸、甜味剂等辅料，然后加入营养原料，搅拌均匀，定容定酸，用高压均质机均值，灌装、杀菌、检验、包装，制成短肽型营养产品。将该短肽型营养产品用于COVID-19患者的营养支持治疗，以提高患者的免疫力。使用方法：200-300ml/次 口服，每日3-4次。
本短肽型肠内营养制剂，按每100克本短肽型营养的营养成分含量为：短肽20.0g、中链脂肪酸20.0g、精氨酸二肽5.0g、支链氨基酸二肽10.0g、蔗糖3.0g、果糖10.0g、麦芽糊精30.0g，并加入维生素、矿物质和微量元素。然后混合、杀菌、检验、包装，制成短肽型营养粉。将该短肽型营养产品用于流感、病毒性肺炎患者的营养支持治疗，以提高患者的免疫力。使用方法：50-100克/次，热开水溶解后口服，每日3-4次。
Claims (8)
- 一种短肽型肠内营养制剂，其特征在于本短肽型肠内营养制剂为预消化型营养补充剂，本短肽型肠内营养制剂用于COVID-19、病毒性肺炎、流感、疱疹的预防和治疗。
- 根据权利要求1所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中短肽的含量为2.0g-10.0g，或者每100克本短肽型肠内营养制剂的粉剂中短肽的含量为10.0g-50.0g。
- 根据权利要求2所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中中链脂肪酸的含量为2.0g-10.0g，或者每100克本短肽型肠内营养制剂的粉剂中中链脂肪酸的含量为10.0g-40.0g。
- 根据权利要求3所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中支链氨基酸或支链氨基酸二肽的含量为0.2g-3.0g，或者每100克本短肽型肠内营养制剂的粉剂中支链氨基酸或支链氨基酸二肽的含量为2.0g-20.0g。
- 根据权利要求4所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中碳水化合物的含量为2.0g-20.0g，或者每100克本短肽型肠内营养制剂的粉剂中碳水化合物的含量为10.0g-60.0g。
- 根据权利要求5所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中精氨酸或精氨酸二肽的含量为0.1g-3.0g，或者每100克本短肽型肠内营养制剂的粉剂中精氨酸或精氨酸二肽的含量为0.5g-10.0g。
- 根据权利要求6所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中乳清短肽的含量为2.0g-15.0g，或者每100克本短肽型肠内营养制剂的粉剂中乳清短肽的含量为10.0g-50.0g。
- 根据权利要求1-7中所述的短肽型肠内营养制剂，其特征在于每100mL本短肽型肠内营养制剂的乳剂中二肽和三肽的含量为2.0g-15.0g，或者每100克本短肽型肠内营养制剂的粉剂中二肽和三肽的含量为10.0g-50.0g。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010452862.3 | 2020-05-25 | ||
| CN202010452862.3A CN111543631A (zh) | 2020-05-25 | 2020-05-25 | 一种短肽型产品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021238644A1 true WO2021238644A1 (zh) | 2021-12-02 |
Family
ID=71999009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/093128 WO2021238644A1 (zh) | 2020-05-25 | 2021-05-11 | 一种短肽型肠内营养制剂 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN111543631A (zh) |
| WO (1) | WO2021238644A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115886250A (zh) * | 2023-01-18 | 2023-04-04 | 美雅健康江苏有限公司 | 一种短肽型肠内全营养食品及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111543631A (zh) * | 2020-05-25 | 2020-08-18 | 张天平 | 一种短肽型产品 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105685973A (zh) * | 2016-02-04 | 2016-06-22 | 贺青 | 一种肠内营养剂 |
| CN107712874A (zh) * | 2017-10-17 | 2018-02-23 | 天津市德恒科技有限公司 | 深度水解蛋白配方粉及工艺制造方法 |
| CN108576827A (zh) * | 2018-02-09 | 2018-09-28 | 丽睿客信息科技（北京）有限公司 | 围手术期营养食品 |
| CN108703376A (zh) * | 2018-05-25 | 2018-10-26 | 上海市浦东医院 | 一种短肽型肠内营养多聚合剂 |
| CN111543631A (zh) * | 2020-05-25 | 2020-08-18 | 张天平 | 一种短肽型产品 |
-
2020
- 2020-05-25 CN CN202010452862.3A patent/CN111543631A/zh active Pending
-
2021
- 2021-05-11 WO PCT/CN2021/093128 patent/WO2021238644A1/zh active Application Filing
- 2021-05-18 CN CN202110537194.9A patent/CN113712194A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105685973A (zh) * | 2016-02-04 | 2016-06-22 | 贺青 | 一种肠内营养剂 |
| CN107712874A (zh) * | 2017-10-17 | 2018-02-23 | 天津市德恒科技有限公司 | 深度水解蛋白配方粉及工艺制造方法 |
| CN108576827A (zh) * | 2018-02-09 | 2018-09-28 | 丽睿客信息科技（北京）有限公司 | 围手术期营养食品 |
| CN108703376A (zh) * | 2018-05-25 | 2018-10-26 | 上海市浦东医院 | 一种短肽型肠内营养多聚合剂 |
| CN111543631A (zh) * | 2020-05-25 | 2020-08-18 | 张天平 | 一种短肽型产品 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115886250A (zh) * | 2023-01-18 | 2023-04-04 | 美雅健康江苏有限公司 | 一种短肽型肠内全营养食品及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113712194A (zh) | 2021-11-30 |
| CN111543631A (zh) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1255456B1 (en) | Use of glutamate or of glutamic acid for the prevention of hyperpermeability or undesired permeability of the intestinal wall | |
| US10821125B2 (en) | Composition comprising FUT2-dependent oligosaccharides and lacto-N-neotetraose for use in promoting brain development and cognition | |
| WO2021238644A1 (zh) | 一种短肽型肠内营养制剂 | |
| CN103476274A (zh) | 具有α-HICA和α-酮戊二酸的营养组合物 | |
| TW201429477A (zh) | 使用人乳寡糖之用於調節炎症之營養調配物 | |
| US11559539B2 (en) | Human milk oligosaccharide for improving immune fitness | |
| ES2377565T3 (es) | Formulación nutricional con alto contenido energético | |
| CA2703042A1 (en) | Formulation to improve gastrointestinal function | |
| CN113194961A (zh) | 用于促进肠道屏障愈合的组合物和方法 | |
| JP2000063284A (ja) | 炎症性腸疾患再燃防止剤 | |
| CN103082167B (zh) | 一种适用于艾滋病患者的复合型肠内营养制剂 | |
| EP2802223B1 (en) | Glutamine enriched nutritional composition for preterm infants | |
| CN107427461B (zh) | 活化乳酸细菌的方法 | |
| JP6300600B2 (ja) | 栄養食品 | |
| AU2016238962B2 (en) | Glutamine enriched nutritional composition for preterm infants | |
| JP3914585B2 (ja) | マクロファージ一酸化窒素産生亢進剤 | |
| CN111264875A (zh) | 一种提高免疫力的短肽 | |
| EP2943082B1 (en) | Improvement of cognitive function in preterm infants that are small for gestational age | |
| CN111358011A (zh) | 一种提高免疫力的短肽 | |
| CN111358010A (zh) | 一种提高免疫力的短肽 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21814106 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21814106 Country of ref document: EP Kind code of ref document: A1 |